Drug Profile
GS 9256
Alternative Names: GS-9256Latest Information Update: 26 Jun 2015
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antivirals
- Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Hepatitis C
Most Recent Events
- 05 Sep 2011 Gilead terminates dosing of tegobuvir in patients receiving a four-drug regimen in a phase IIb trial of GS 9256
- 01 Sep 2011 Pharmacodynamics data from early research in Hepatitis C presented at the 242nd American Chemical Society National Meeting (ACS-2011)
- 18 Aug 2011 Gilead Sciences completes enrolment in its phase II trial for Hepatitis C in USA, Canada & European Union (NCT01225380)